These topics were tagged with "Hepatitis"
-
25/05/2013 - Hepatitis C treatment gap in Europe: France doing well but Italy treated fewer than one in a hundred patients in 2010
France led the world in the proportion of its hepatitis C patients who received treatment in 2010, but some countries in southern and eastern Europe had treatment rates that were almost tenfold low... -
25/05/2013 - The majority of physicians that treat hepatitis C virus (HCV) have begun “warehousing” and preparing their HCV patients for the next generation of HCV treatments
Sixty percent of surveyed physicians agree that they are beginning to warehouse HCV patients until new interferon-free regimens are available, according to a recently published BioTrends r... -
25/05/2013 - Spring Bank Pharmaceuticals starts Phase I study of SB 9200 for treatment of HCV infection
MILFORD, Mass., May 23, 2013 /PRNewswire/ -- Spring Bank Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines for the treatment of viral infections, today announced th... -
25/05/2013 - DDW 2013: Does treating herpes help suppress hepatitis C virus?
Treating herpes simplex virus type 2 (HSV-2) with valacyclovir (Valtrex) was associated with a substantial reduction in plasma hepatitis C virus levels in dually-infected individuals, according to ... -
25/05/2013 - DDW 2013: Viral breakthrough may occur during interferon/ribavirin 'tail' of HCV triple therapy
HCV viral breakthrough is an ongoing possibility during the pegylated interferon/ribavirin continuation phase after triple therapy with telaprevir (Incivek or Incivek or Incivo), especially for dif... -
25/05/2013 - DDW 2013: Advanced fibrosis does not affect response to faldaprevir all-oral regimen
An interferon-free combination of faldaprevir, BI 207127, and ribavirin produced high and similar sustained response rates for treatment-naive genotype 1b hepatitis C patie... -
25/05/2013 - EASL 2013: HIV/HCV coinfected at risk for decompensation, may need prompt treatment
HIV positive people with hepatitis C coinfection may experience liver decompensation with advanced fibrosis, even before they progress to cirrhosis, and may therefore benefit fr... -
22/05/2013 - Primary efficacy and safety findings from Phase 3 study of Janssen’s simeprevir administered once daily demonstrate sustained virologic response in treatment-experienced genotype 1 chronic hepatitis C adult patients
ORLANDO, Fla. (May 21, 2013) -- Janssen R&D Ireland (Janssen) today announced primary efficacy and safety results from the global Phase 3 PROMISE study demonstrating that use of the investigati... -
22/05/2013 - Global health community renew commitment to tackling viral hepatitis at 66th World Health Assembly
May 21, 2013--Switzerland, Geneva--Ministers of Health and global health advocates from across the world yesterday committed to prioritising viral hepatitis as an urgent public health issue at a me... -
22/05/2013 - European Medicines Agency validates Gilead’s Marketing Application for sofosbuvir for the treatment of hepatitis C
Once-daily sofosbuvir will receive an accelerated assessment by EMA Designation granted to new medicines of major public health interest FOSTER CITY, Calif.--(BUSINESS WIRE)--May. 21, 2013... -
22/05/2013 - Interferon-free, treat-all approach cost effective, beneficial for chronic HCV
ORLANDO, Fla. — An orally administered, interferon-free regimen with a treat-all approach for patients with chronic hepatitis C may be more beneficial and more cost effective than interferon-... -
20/05/2013 - Current and future therapies for hepatitis C virus infection
Only 20 years after the discovery of the hepatitis C virus (HCV), a cure is now likely for most people affected by this chronic infection, which carries a substantial disease burden, not only in th... -
16/05/2013 - Hepatitis E virus infection can cause rapid liver cirrhosis in people with HIV who have low CD4 cell counts
Treatment with ribavirin partially effective Infection with hepatitis E virus (HEV) can cause rapid liver fibrosis in people with HIV who have low CD4 cell counts, case reports publish... -
16/05/2013 - Antiretrovirals linked to liver fibrosis
AMSTERDAM, the Netherlands — Despite hepatitis B virus suppression provided by current drugs, many patients coinfected with hepatitis B and HIV have advanced liver fibrosis, accordi... -
13/05/2013 - U.S. FDA grants Priority Review to simeprevir (TMC435) for combination treatment of genotype 1 chronic hepatitis C
RARITAN, N.J., May 13, 2013 – Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the New Drug Ap... -
13/05/2013 - In Brazil, Mexico and Argentina, dual combination therapy with Peg-IFN-alpha and ribavirin remains the most commonly prescribed treatment for all hepatitis C virus-infected patients
However, recent changes in Brazil and Argentina are expected to drive a shift in treatment of HCV genotype 1 infections, according to a new report from Decision Resources May 13, 2013—Bur... -
10/05/2013 - Early hepatitis C treatment may not be cost-saving in France - but early diagnosis will save money
Treating hepatitis C earlier than recommended by current French and European treatment guidelines, before the development of severe liver fibrosis, may not result in substantial cost savings even i... -
10/05/2013 - Pretreatment anemia raises mortality risk among HCV/HIV coinfected patients
Patients coinfected with hepatitis C and HIV are at increased risk for death with the presence of pretreatment anemia, while the initiation of therapy for HCV improves survival in this population, ... -
09/05/2013 - Movement for global access to hepatitis C treatment building momentum
Access to hepatitis C treatment in low- and middle-income countries is being restricted by the high cost of interferon and a lack of commitment to treating the disease, leading to a growin... -
09/05/2013 - MSF: Diagnosis and treatment of hepatitis C: A technical landscape
Opportunities to revolutionise care in developing countries This report provides an overview on the current state of play and a framework for action with regards to hepatitis C diagnost... -
08/05/2013 - Report highlights major failings in UK response to hepatitis C
The UK needs to “be doing so much more” in response to hepatitis C, according to a new report. Supported by a consortium of leading hepatitis C charities, Confronting the silen... -
08/05/2013 - CDC: Hepatitis C testing requires both antibody screening and HCV RNA follow-up
Half of all people who receive an initial hepatitis C virus (HCV) antibody screening test never return for follow-up viral load testing to determine if they are still infected, according to a recen... -
08/05/2013 - EASL 2013: Vaniprevir boosts interferon/ribavirin response rate for prior non-responders with cirrhosis
The next-generation HCV protease inhibitor vaniprevir (MK-7009) increased post-treatment sustained response rates for previously treated genotype 1 chronic hepatitis C patients with liver cirrhosis... -
06/05/2013 - AbbVie's investigational HCV regimen receives Breakthrough Therapy designation from the U.S. Food and Drug Administration
Interferon-free, direct-acting antiviral combination therapy currently in Phase 3 development NORTH CHICAGO, Ill., May 6, 2013 -- AbbVie (NYSE: ABBV) today announced that its investigation... -
06/05/2013 - New antiviral treatment could significantly reduce global burden of hepatitis C
Scientists show potential impact of therapy in reducing transmission in UK, Canada and Australia Around 150 million people globally are chronically infected with the hepatitis C virus (HC... -
06/05/2013 - Does HBV suppression with entecavir affect clinical outcomes?
Evidence from an ongoing prospective cohort study indicates yes, but only in patients with cirrhosis, and only when virologic response is strong. Suppression of hepatitis B virus (HBV) with an... -
02/05/2013 - Combination drugs are the future of the European hepatitis B and C therapeutics markets, says Frost & Sullivan
Benefits include improved drug efficiency, reduced pill burden, and lower dosage frequency LONDON - 30 April 2013 - The limited efficacy and negative side-effects associated with current therap... -
02/05/2013 - EASL 2013: Truvada works best for immune-tolerant hepatitis B patients -- but do they need treatment?
A combination of tenofovir and emtricitabine (the drugs in Truvada) suppressed hepatitis B virus (HBV) replication more than tenofovir alone over 4 years for people with inactive or immune-tolerant... -
02/05/2013 - Discovery of a more than 82 million years old hepatitis B virus
Scientists of Münster University were able to detect prehistoric hepatitis B viruses in bird genomes/Publication in "Nature Communications" The liver inflammation hepatitis B com... -
02/05/2013 - Vertex Pharmaceuticals swings to 1st-quarter loss on write-down
Vertex Pharmaceuticals Inc. (VRTX) swung to a first-quarter loss on a write-down tied to its hepatitis C program, as sales of Incivek also slid. The pharmaceutical company has now reported four...
News
You can also search the entire site for "Hepatitis" by clicking here